WuXi PharmaTech Announces Fourth-Quarter and Full-Year 20...(S outstanding- basic (Note 3) ...)

Date:3/25/2009

S outstanding- basic (Note 3) 66,035,918 61,528,350 63,775,220 38,506,277 Diluted net earnings (loss) per ADS: Earnings (loss) from continuing operations (0.74) 0.17 * (0.23) 0.42 * Loss on discontinued operations-net of tax (Note 1) (0.68) -- * (0.78) -- * Net earnings (loss) per ADS (1.42) 0.17 * (1.01) 0.42 * Weighted average ADS outstanding- diluted (Note 3) 66,035,918 72,544,322 63,775,220 64,393,436 * Not meaningful Note 2: Fourth-quarter 2008 net revenues for Laboratory Services is comprised of $42.3 million for China-based Laboratory Services and $15.1 million for U.S. testing. Fourth-quarter and full-year 2007 amounts relate entirely to China-based Laboratory Services. Full-year 2008 net revenues for Laboratory Services is comprised of $147.3 million for China-based Laboratory Services and $57.7 million for U.S. testing services. Note 3: Eight (8) ordinary shares are equal to one (1) ADS. Common share equivalents are not reflected in calculation of weighted average ADS outstanding -- diluted for fourth-quarter and full-year 2008 because, given the net loss in the quarter and full year, the effect of their inclusion would be antidilutive. Note 4: Financial results of AppTec were consolidated as of January 31, 2008. WUXI PHARMATECH (CAYMAN) INC. DISCONTINUED OPERATIONS OF BIOLOGICS MANUFACTURING (In thousands of U.S. dollars) Three Months Ended Year Ended December 31, December 31,
'/>"/>

SOURCE WuXi PharmaTech (Cayman) Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20
Related biology technology :

1. The Fitzsimons Redevelopment Authority Selects Pharmatech Oncology as Preferred Vendor
2. Quest PharmaTech Announces Strategic Alliance with IntelligentNano to Develop Nanotechnology-Based Next Generation SL052
3. Quest PharmaTech Announces Results Showing its Photosensitizer, SL052, is an Effective Immuno-Stimulant when combined with Immunotherapy for the Removal of Solid Tumors
4. Quest PharmaTech Announces a Review of Strategic Alternatives to Enhance Shareholder Value
5. WuXi PharmaTech to Present at 27th Annual J.P. Morgan Healthcare Conference
6. Pharmatech 2.0: Introducing Pharmatech Oncology
7. WuXi PharmaTech Will Focus U.S. Operations on Laboratory Testing Services
8. WuXi PharmaTech Appoints Ying Han to Its Board of Directors
9. WuXi PharmaTech Announces Third Quarter 2008 Results
10. WuXi PharmaTech Signs New Collaboration Agreement With Pfizer
11. WuXi PharmaTech Schedules Third Quarter 2008 Earnings Release on Wednesday, November 12, 2008